Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease

Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, New York 10032, USA.
New England Journal of Medicine (Impact Factor: 55.87). 10/2012; 367(16):1497-507. DOI: 10.1056/NEJMoa1114058
Source: PubMed


Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.
Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse of psychosis or agitation.
A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily). The severity of psychosis and agitation were reduced, although there was a mild increase in extrapyramidal signs; 112 patients met the criteria for response to treatment, of whom 110 underwent randomization. In the first 16 weeks after randomization, the rate of relapse was higher in the group that received placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33% [23 of 70 in groups 1 and 2]; P=0.004; hazard ratio with placebo, 1.94; 95% confidence interval [CI], 1.09 to 3.45; P=0.02). During the next 16 weeks, the rate of relapse was higher in the group that was switched from risperidone to placebo than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15% [2 of 13 in group 1]; P=0.02; hazard ratio, 4.88; 95% CI, 1.08 to 21.98; P=0.02). The rates of adverse events and death after randomization did not differ significantly among the groups, although comparisons were based on small numbers of patients, especially during the final 16 weeks.
In patients with Alzheimer's disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse. (Funded by the National Institutes of Health and others; number, NCT00417482.).

Download full-text


Available from: Gregory H Pelton, Jan 28, 2014
  • Source
    • "Furthermore, emerging evidence is confirming what would intuitively be feared as a result of NPS under treatment. When previously helpful medications are withdrawn, NPS can resurface and quality of life can suffer [19] [20] [21]. Quality of life must also be protected by our ongoing efforts to identify and treat common problems contributing to NPS, such as delirium and pain [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Degenerative forms of dementia are progressive, incurable, fatal, and likely to cause suffering in conjunction with personal incapacity. Timely diagnostic disclosure and counseling can facilitate important advance care planning. The risk of harm associated with neuropsychiatric symptoms (NPS) of dementia often has to be balanced against the risk of harm associated with medication management of NPS. A palliative care framework can help preserve autonomy, quality of life, comfort, and dignity for patients with NPS.
    06/2013; 2013(12):230134. DOI:10.1155/2013/230134
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antipsychotic agents long-term use for this indication. Their effectiveness is limited and there is concern about adverse effects, including higher mortality with long-term use. When behavioural strategies have failed and drug therapy is instituted, regular attempts to withdraw these drugs are recommended. measures. Our primary efficacy outcomes were success of withdrawal (i.e. remaining in study off antipsychotics) and NPS. Eight of nine trials significantly shorter in the discontinuation group (Chi(2) = 4.1, P value = 0.04). The ninth trial included people with psychosis or (NPI)-core score of 30% or greater (P value = 0.004, hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.09 to 3.45 at four months). The only outcome that could be pooled was the full NPI-score, used in two months (mean difference (MD) -1.49, 95% CI -5.39 to 2.40). These two studies reported subgroup analyses according to baseline NPI-score (14 or less versus > 14). In one study, those with milder symptoms at discontinuation group (NPI-agitation, Mann-Whitney U test z = 2.4, P value = 0.018). In both studies, there was evidence of significant behavioural deterioration in people with more severe baseline NPS who were withdrawn from antipsychotics (Chi(2) = 6.8; P value = 0.009 for the marked symptom score in one study).Individual studies did not report (5% to 8% greater than placebo, depending on the population analysed, measured at 12 months). This trend became significant three years after randomisation, but due to dropout and uncertainty about the use of withdrawal might not be recommended.
    Cochrane database of systematic reviews (Online) 03/2013; 3(3):CD007726. DOI:10.1002/14651858.CD007726.pub2 · 6.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The evolution of neuroleptic prescriptions in an elderly population over a decade. Methods This retrospective study compares the prescriptions of neuroleptics in a geriatric hospital between 2000 and 2010, calculating the average dose of a neuroleptic in equivalent to haloperidol. The study analyses this dose when associated with a specific treatment for dementia in accordance with the recommendations of the HAS. Results We notice a 15% increase of the neuroleptic dose prescribed, although the dose of neuroleptic collectively admitted for a demented patient is respected. This can be explained by the evolution of the population of hospitalised patients. Conclusion This study shows the interest of following-up the prescriptions of neuroleptics. It underlines the interest of a more precise analysis of the prescriptions, so as to implement a strategy to control the use of neuroleptics in geriatrics.
    NPG Neurologie - Psychiatrie - Gériatrie 01/2013; 14(79). DOI:10.1016/j.npg.2013.06.007
Show more